Trials / Recruiting
RecruitingNCT06884540
Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies: The OPUS Anesthesia Pilot Trial
Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies (OPUS) Anesthesia: a Pilot Randomised Controlled Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- CHU de Quebec-Universite Laval · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Up to 40% of patients experience suboptimal recovery in the days following major surgery, limiting their return to functional independence. Few preventive interventions exist, but intravenous dexmedetomidine and lidocaine administered during general anesthesia represent simple strategies that may significantly impact recovery and other patient-centred outcomes after surgery. The goal of this pilot trial is to determine the feasibility of conducting a phase 3 pragmatic adaptive multicentre trial to evaluate the impact of dexmedetomidine and lidocaine administered during major non-cardiac surgery on patient-centred outcomes.
Conditions
- Anesthesia
- Anesthesia Complication
- Surgery
- Quality of Life
- Pain, Postoperative
- Anesthesia Morbidity
- Feasibility Studies
- Patient-centredness
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine | Intravenous bolus: between 0.2 and 0.5 mcg/kg. followed by Intravenous infusion: ranging from 0.2 to 0.7 mcg/kg/h to the discretion of the attending anesthesiologist. Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure. |
| DRUG | lidocaine | Intravenous bolus: between 0.5 and 1.5 mg/kg. followed by Intravenous infusion: ranging from 0.5 to 2.0 mg/kg/h to the discretion of the attending anesthesiologist. Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure. |
| OTHER | control group | Usual care where systemic dexmedetomidine is not allowed and systemic lidocaine is permitted only for the prevention or treatment of propofol injection pain. |
Timeline
- Start date
- 2025-07-15
- Primary completion
- 2027-04-01
- Completion
- 2027-10-01
- First posted
- 2025-03-19
- Last updated
- 2025-07-29
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06884540. Inclusion in this directory is not an endorsement.